Shchuko A G, Zlobin I V, Yur'eva T N, Ostanin A A, Chernykh E R
Irkutsk branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 337 Lermontova St., Irkutsk, Russian Federation, 664033; Irkutsk State Medical University, 1 Krasnogo vosstaniya St., Irkutsk, Russian Federation, 664003.
Irkutsk branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 337 Lermontova St., Irkutsk, Russian Federation, 664033; Irkutsk State Medical Academy of Continuing Education, 100 Yubileynyy mikrorayon, Irkutsk, Russian Federation, 664049.
Vestn Oftalmol. 2015 Mar-Apr;131(2):50-58. doi: 10.17116/oftalma2015131250-58.
To study the concentrations of intraocular cytokines in patients with retinal vein occlusion (RVO) before and after intravitreal ranibizumab injection and to compare the results with clinical activity of the disease and treatment efficacy.
A comprehensive ophthalmological examination of 44 patients with RVO and macular edema was performed. Intraocular fluid was first collected before the intravitreal injection. Cytokines concentrations were measured using Bio-Plex Pro Human Cytokine 27-plex Panel (Bio-Rad Laboratories, USA) for flow cytometry. The test was repeated 1 month after the injection.
A total of 11 cytokines were reliably detected. After ranibizumab injections certain angiogenic (VEGF) and proinflammatory (IL-6, IL-8, IL-13, IL-15, MCP-1) factors appeared to be significantly suppressed. Clinical efficacy of the therapy correlated with the degree of cytokines suppression, which in turn depended on the severity of ocular involvement at baseline.
Retinal vein occlusion pathogenesis involves a cascade of immune and inflammatory processes, including activation of not only VEGF but also quite a few inflammatory and chemotactic factors, whose activity depends on the extent of ischemic damage in the retina.
研究玻璃体内注射雷珠单抗前后视网膜静脉阻塞（RVO）患者眼内细胞因子的浓度，并将结果与疾病的临床活动度和治疗效果进行比较。
对44例患有RVO和黄斑水肿的患者进行了全面的眼科检查。首先在玻璃体内注射前收集眼内液。使用Bio-Plex Pro Human Cytokine 27-plex Panel（美国伯乐公司）通过流式细胞术测量细胞因子浓度。注射后1个月重复该检测。
共可靠检测到11种细胞因子。注射雷珠单抗后，某些血管生成（VEGF）和促炎（IL-6、IL-8、IL-13、IL-15、MCP-1）因子似乎受到显著抑制。治疗的临床疗效与细胞因子的抑制程度相关，而细胞因子的抑制程度又取决于基线时眼部受累的严重程度。
视网膜静脉阻塞的发病机制涉及一系列免疫和炎症过程，不仅包括VEGF的激活，还包括相当多的炎症和趋化因子的激活，其活性取决于视网膜缺血损伤的程度。
